LEAP-009: Phase 2 study of lenvatinib with or without pembrolizumab vs chemotherapy for the treatment of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) upon progression after platinum and immunotherapy (PD-1/PD-L1 inhibition)
Harrington, K. J. Kim, H. R. Salas, S. Oliva, M. Metcalf, Robert Bernsdorf, M. Kim, J. W. Cohen, E. E. W. Siu, L. Rischin, D.
Harrington, K. J.
Kim, H. R.
Salas, S.
Oliva, M.
Metcalf, Robert
Bernsdorf, M.
Kim, J. W.
Cohen, E. E. W.
Siu, L.
Rischin, D.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Harrington KJ, Kim HR, Salas S, Oliva M, Metcalf R, Bernsdorf M, et al. LEAP-009: Phase 2 study of lenvatinib with or without pembrolizumab vs chemotherapy for the treatment of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) upon progression after platinum and immunotherapy (PD-1/PD-L1 inhibition). Asia-Pacific Journal of Clinical Oncology. 2022 Nov;18:126-7. PubMed PMID: WOS:000871956500177.